ATE416764T1 - Behandlungsmethoden während eingriffen in das gefässsystem - Google Patents

Behandlungsmethoden während eingriffen in das gefässsystem

Info

Publication number
ATE416764T1
ATE416764T1 AT03809618T AT03809618T ATE416764T1 AT E416764 T1 ATE416764 T1 AT E416764T1 AT 03809618 T AT03809618 T AT 03809618T AT 03809618 T AT03809618 T AT 03809618T AT E416764 T1 ATE416764 T1 AT E416764T1
Authority
AT
Austria
Prior art keywords
treatment methods
vascular system
vascular
methods during
during interventions
Prior art date
Application number
AT03809618T
Other languages
English (en)
Inventor
Roshantha Chandraratna
Yang-Dar Yuan
Tuong Dang
Sheng Loh
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE416764T1 publication Critical patent/ATE416764T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03809618T 2002-10-22 2003-10-21 Behandlungsmethoden während eingriffen in das gefässsystem ATE416764T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/278,770 US7105566B2 (en) 2002-10-22 2002-10-22 Methods of treatment during vascular procedures

Publications (1)

Publication Number Publication Date
ATE416764T1 true ATE416764T1 (de) 2008-12-15

Family

ID=32093435

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03809618T ATE416764T1 (de) 2002-10-22 2003-10-21 Behandlungsmethoden während eingriffen in das gefässsystem

Country Status (6)

Country Link
US (1) US7105566B2 (de)
EP (1) EP1558235B1 (de)
AT (1) ATE416764T1 (de)
AU (1) AU2003301673A1 (de)
DE (1) DE60325261D1 (de)
WO (1) WO2004037243A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054468A1 (ja) * 2003-12-01 2005-06-16 Reverse Proteomics Research Institute Co., Ltd. 抗糖尿病剤の標的タンパク質及び対応する新規抗糖尿病剤「インスフル」
BRPI0616454A2 (pt) 2005-09-30 2011-06-21 Vitae Pharmaceuticals, Inc. métodos de tratamento de cáncer
DK2026778T3 (en) * 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
GB0915196D0 (en) * 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
MX352727B (es) 2011-12-13 2017-12-06 Dartmouth College Tratamiento de trastorno autoinmune al usar agonistas de rxr.
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
WO2017075607A1 (en) 2015-10-31 2017-05-04 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of pxr agonists and thyroid hormones
KR20180121983A (ko) 2016-03-10 2018-11-09 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
CA3016876C (en) 2016-03-10 2021-12-28 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US12492177B2 (en) 2019-12-19 2025-12-09 Orphagen Pharmaceuticals, Inc. RAR-α compounds for inflammatory disease and male contraception
CA3217096A1 (en) * 2021-05-04 2022-11-10 Ingrid Gunda Georg Contraceptive compounds and methods
MX2024006978A (es) 2021-12-07 2024-07-19 Io Therapeutics Inc Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+.
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014777A1 (en) 1992-12-28 1994-07-07 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US6218128B1 (en) * 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US6008204A (en) * 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
CA2233888A1 (en) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
FR2753627B1 (fr) * 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
US6037488A (en) * 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
KR100440836B1 (ko) * 1997-11-12 2004-07-19 에프. 호프만-라 로슈 아게 레티노이드 길항제를 이용한 제2형 ｔ-보조세포 중재 면역질환의 치료
US6521641B1 (en) * 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
US6713515B2 (en) 2000-09-13 2004-03-30 Bristol Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
US20020193403A1 (en) * 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
EP1427399A2 (de) * 2001-09-17 2004-06-16 The University Of Western Ontario Pan-antagonisten des retinoidrezeptors zur stimulierung der chondrogenese

Also Published As

Publication number Publication date
EP1558235B1 (de) 2008-12-10
AU2003301673A1 (en) 2004-05-13
WO2004037243A2 (en) 2004-05-06
US7105566B2 (en) 2006-09-12
US20040077710A1 (en) 2004-04-22
DE60325261D1 (de) 2009-01-22
WO2004037243A3 (en) 2004-09-30
EP1558235A2 (de) 2005-08-03

Similar Documents

Publication Publication Date Title
ATE416764T1 (de) Behandlungsmethoden während eingriffen in das gefässsystem
Schaden et al. Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
ATE524070T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
ATE339957T1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE506019T1 (de) Kontrollierbare vorrichtung und kit zur behandlung von störungen des herzrhythmus- reguliersystems
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
Fredrickson et al. Low-volume ultrasound-guided nerve block provides inferior postoperative analgesia compared to a higher-volume landmark technique
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
CY1107352T1 (el) Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου
DE60326548D1 (de) Verfahren zur verhütung oder behandlung von herzarrhythmie
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
DE69920015D1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
WO2003082263A8 (en) Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
RU2284155C1 (ru) Способ субфасциальной диссекции перфорантных вен голени при хронической венозной недостаточности
RU2456004C1 (ru) Способ восстановления гемостатических нарушений при переломах костей конечностей
Jagtman et al. Compression sclerotherapy of anterolateral thigh primary varicose veins (lateral accessory saphenous varicose veins): a prospective five-year follow-up study
Tsirkin et al. Effect of Physical Training on Blood Level of Endogenous Modulators of β-Adreno-and μ-Cholinoreactivity in Patients with a History of Myocardial Infarction
UA78009U (uk) Спосіб хірургічного лікування варикозних вен нижніх кінцівок
EP4527316A4 (de) Vorrichtung zur behandlung der saphenavene und zugehörigen varizen sowie verfahren zu ihrer verwendung im menschlichen körper

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties